TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 P&L / Income Statement

TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (2 categories). Revenue and costs use their disclosed categories.

Total revenue

169,584,000 US dollars

Cost of goods sold

2,174,000 US dollars

Gross profit (calculated)

167,410,000 US dollars

Operating expenses (calculated)

163,456,000 US dollars

Operating income (loss)

3,954,000 US dollars

Total other (expense) income, net

negative 38,955,000 US dollars

Loss from continuing operations before income tax

negative 35,001,000 US dollars

Income tax benefit (provision) on continuing operations

negative 204,000 US dollars

Net loss

negative 34,797,000 US dollars

Net product sales revenue

161,352,000 US dollars

License and collaboration revenue revenue

8,232,000 US dollars

Net product sales cost of revenue

2,174,000 US dollars

License and collaboration revenue cost of revenue

0 US dollars

Selling, general and administrative

96,112,000 US dollars

Research and development

60,283,000 US dollars

Royalty expense

7,061,000 US dollars

Loss from discontinued operations, net of tax

0 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.